Chronic Pancreatitis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, and Others), By Causes (Damaged Pancreatic Duct, Cancer, Auto-Immune Disorder, Cystic Fibrosis, Gall Stones, and Hereditary), By Diagnosis (CT Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, and Others), By Route of Administration (Oral, Parenteral), By End Users (Hospitals, Clinics, Others) and Region Forecast 2020-2031

Chronic Pancreatitis Market size was valued at US$ 1.8 billion in 2024 and is expected to reach US$ 2.8 billion by 2031, growing at a significant CAGR of 3.5% from 2025-2031. Chronic Pancreatitis is a long-standing inflammation of the pancreas that alters the organ’s normal structure and functions, has symptoms such as upper abdominal pain, nausea and vomiting, steatorrhea, weight loss, and diabetes type I, and the causes of the disease include alcoholism, autoimmune disorders, intraductal obstruction, idiopathic pancreatitis, tumors, ischemia, and others.

According to the Global Burden of Disease (2017), the global estimation of incidence and mortality was 9.62 cases per 1,00,000 person-years and 0.09 deaths per 1,00,000 person-years, respectively for chronic pancreatitis. An increase in consumption of alcohol and a rise in unhealthy lifestyles will act as the growth drivers for the market. However, the high cost of treatment will have a restraining impact on the market growth. Technological advancements and increasing healthcare expenditure are the opportunities for market expansion.

Key Developments

• In Dec 2021, Kangen Pharmaceuticals completed a phase-I/II trial in pancreatitis in the USA, for NI-03.
• In July 2023, First Wave BioPharma announced its intention to submit BLA for Adrulipase alfa to the US FDA for exocrine pancreatic insufficiency.